Biomea Fusion Inc., a clinical-stage diabetes and obesity medicines company, announced new preclinical findings from a 28-day weight loss study involving its investigational oral GLP-1 receptor agonist candidate, BMF-650. The study, conducted in obese cynomolgus monkeys, demonstrated significant dose-dependent reductions in food intake and marked weight loss, with average reductions of 12% and 15% over the treatment period. The data suggest that BMF-650 compares favorably to other leading GLP-1 receptor agonist candidates in development. Biomea Fusion plans to submit an Investigational New Drug $(IND.AU)$ application in the second half of 2025, with a Phase I trial in obese, otherwise healthy volunteers expected to begin in late 2025, pending IND clearance. The full set of preclinical data is scheduled for submission and presentation at an upcoming medical conference.